Pretomanid in the Treatment of Patients with Tuberculosis in the United States

  • Goswami, Neela D. M.D., M.P.H.
  • Ashkin, David M.D.
  • Haley, Connie A. M.D.

  • 1 Centers for Disease Control and Prevention, Atlanta, GA [email protected]

    2 University of Florida, Gainesville, FL

*A list of the BAM Project Team investigators is available in the Supplementary Appendix, available at NEJM.org.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

New England Journal of Medicine 387(9):p 850-852, September 1, 2022. | DOI: 10.1056/NEJMc2119461

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

  • Conradie, Francesca M.B., B.Ch.
  • Bagdasaryan, Tatevik R. M.D.
  • Borisov, Sergey M.D.
  • Howell, Pauline M.D.
  • Mikiashvili, Lali M.D.
  • Ngubane, Nosipho M.D.
  • Samoilova, Anastasia M.D.
  • Skornykova, Sergey M.D.
  • Tudor, Elena M.D.
  • Variava, Ebrahim M.D.
  • Yablonskiy, Petr Ph.D.
  • Everitt, Daniel M.D.
  • Wills, Genevieve H. M.Sc.
  • Sun, Eugene M.D.
  • Olugbosi, Morounfolu M.D.
  • Egizi, Erica M.P.H.
  • Li, Mengchun M.D.
  • Holsta, Alda M.D.
  • Timm, Juliano Ph.D.
  • Bateson, Anna Ph.D.
  • Crook, Angela M. Ph.D.
  • Fabiane, Stella M. Ph.D.
  • Hunt, Robert B.Sc.
  • McHugh, Timothy D. Ph.D.
  • Tweed, Conor D. M.D.
  • Foraida, Salah M.D.
  • Mendel, Carl M. M.D.
  • Spigelman, Melvin M.D.
New England Journal of Medicine 387(9):p 810-823, September 1, 2022. | DOI: 10.1056/NEJMoa2119430
Copyright © 2022 Massachusetts Medical Society. All rights reserved.
View full text|Download PDF